摘要
目的评估聚乙二醇干扰素α-2a与拉米夫定治疗HBeAg阳性慢性乙型肝炎的成本效果。方法运用相关文献资料和Delphi专家咨询数据,采用Markov模型对聚乙二醇干扰素α-2a与拉米夫定治疗慢性乙型肝炎疗效进行经济学评价。结果与使用拉米夫定1～4年比较,使用聚乙二醇干扰素α-2a治疗HBeAg阳性慢性乙型肝炎患者1年,人均延长寿命0.52～0.79年,每延长1年寿命所需增加的医疗费用为16563～18954元。结论使用聚乙二醇干扰素α-2a 1年相比于使用拉米夫定1～4年治疗HBeAg阳性慢性乙型肝炎具有更好的成本效果。
Objective To assess the long-term cost-effectiveness of peginterferon α-2a and lamivudine in the treatment of HBeAg-positive chronic hepatitis B（CHB） patients. Methods A Markov model was employed to conduct the economic evaluation based on the data retrieved from literatures and verified through Delphi method. Results Compared with 1-4 years lamivudine treatment, oneyear peginterferon α-2a treatment could prolong 0.52-0.79 year of life for every HBeAg-positive CHB patient and the incremental medical cost was 16 563-18 954 RMB per life-year saved. Conclusion Peginterferon α-2a is more cost effective than lamivudine in the treatment of HBeAg-positive chronic hepatitis B.
出处
《中华传染病杂志》
CAS
CSCD
北大核心
2007年第8期468-472,共5页
Chinese Journal of Infectious Diseases
